Clinical Trial

Contralateral Resistance Training During Immobilization in Patients With Acromioclavicular Joint Injury

Study acronym: CROSS-ACD
Recruiting
View on ClinicalTrials.gov →
Summary
This randomized controlled trial aims to compare the effects of contralateral eccentric and concentric resistance training performed during the immobilization period following acromioclavicular joint injury. Immobilization is commonly prescribed after injury but may lead to reductions in muscle mass, neuromuscular function, force production, and upper-limb functionality. Contralateral resistance training, also known as cross-education training, involves exercising the non-injured limb to induce beneficial adaptations in the immobilized limb through neural mechanisms. While both eccentric and concentric exercise may produce contralateral effects, their relative effectiveness in a clinical population remains unclear. Participants with acute acromioclavicular joint injury requiring sling immobilization will be randomly assigned to either a contralateral eccentric training group or a contralateral concentric training group. During immobilization, participants will perform supervised resistance training with the non-injured upper limb. Following immobilization, all participants will receive the same standardized rehabilitation program. Neuromuscular function, muscle morphology, force production, upper-limb function, and quality of life will be assessed before immobilization, after immobilization, and following rehabilitation. The findings may contribute to the development of more effective rehabilitation strategies for patients recovering from upper-limb injuries requiring temporary immobilization.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-29.
Trial Details
NCT Number NCT07628361
Lead Sponsor Universidad Nacional Andres Bello
Conditions Acromioclavicular Joint Injury, Acromioclavicular Joint Dislocation
Enrollment 16 participants
Start Date 2026-01-01
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-08